Andrew Liu
Concepts (402)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Asthma | 94 | 2025 | 2295 | 7.840 |
Why?
| | Hypersensitivity | 16 | 2023 | 257 | 3.330 |
Why?
| | Urban Population | 18 | 2024 | 479 | 3.160 |
Why?
| | Anti-Asthmatic Agents | 16 | 2024 | 395 | 1.650 |
Why?
| | Environmental Exposure | 10 | 2025 | 579 | 1.540 |
Why?
| | Severity of Illness Index | 18 | 2025 | 2828 | 1.270 |
Why?
| | Allergens | 17 | 2022 | 409 | 1.070 |
Why?
| | Child | 80 | 2025 | 21935 | 1.070 |
Why?
| | Oscillometry | 4 | 2025 | 42 | 1.000 |
Why?
| | Virus Diseases | 4 | 2022 | 212 | 1.000 |
Why?
| | Nasal Mucosa | 6 | 2019 | 107 | 0.980 |
Why?
| | Endotoxins | 4 | 2013 | 220 | 0.850 |
Why?
| | Immunoglobulin E | 21 | 2020 | 342 | 0.840 |
Why?
| | Rhinitis | 5 | 2018 | 158 | 0.810 |
Why?
| | Poverty | 7 | 2016 | 521 | 0.790 |
Why?
| | Omalizumab | 9 | 2020 | 51 | 0.790 |
Why?
| | Airway Resistance | 3 | 2025 | 41 | 0.780 |
Why?
| | Child, Preschool | 40 | 2025 | 11074 | 0.750 |
Why?
| | Adrenal Cortex Hormones | 11 | 2025 | 565 | 0.730 |
Why?
| | Phenotype | 7 | 2018 | 3196 | 0.720 |
Why?
| | Air Pollution, Indoor | 3 | 2025 | 180 | 0.710 |
Why?
| | Respiratory Sounds | 9 | 2024 | 125 | 0.680 |
Why?
| | Respiratory Function Tests | 9 | 2025 | 600 | 0.670 |
Why?
| | Food Hypersensitivity | 3 | 2014 | 183 | 0.650 |
Why?
| | Hygiene | 4 | 2015 | 30 | 0.650 |
Why?
| | Biological Products | 1 | 2023 | 216 | 0.630 |
Why?
| | Humans | 116 | 2025 | 137585 | 0.620 |
Why?
| | Bronchodilator Agents | 8 | 2025 | 252 | 0.620 |
Why?
| | Inhalation Exposure | 2 | 2025 | 105 | 0.610 |
Why?
| | Adolescent | 46 | 2025 | 21513 | 0.580 |
Why?
| | Respiratory Syncytial Virus, Human | 1 | 2018 | 74 | 0.550 |
Why?
| | Rhinovirus | 8 | 2024 | 58 | 0.540 |
Why?
| | Microbiota | 4 | 2022 | 762 | 0.540 |
Why?
| | Disease Progression | 14 | 2025 | 2757 | 0.520 |
Why?
| | Hygiene Hypothesis | 1 | 2015 | 1 | 0.490 |
Why?
| | Biological Therapy | 1 | 2015 | 29 | 0.480 |
Why?
| | Air Pollutants | 2 | 2025 | 430 | 0.460 |
Why?
| | Male | 67 | 2025 | 67762 | 0.440 |
Why?
| | Dust | 5 | 2021 | 100 | 0.440 |
Why?
| | Prevalence | 10 | 2018 | 2734 | 0.430 |
Why?
| | Peanut Hypersensitivity | 5 | 2015 | 146 | 0.430 |
Why?
| | Female | 68 | 2025 | 73304 | 0.420 |
Why?
| | Nitrogen Dioxide | 1 | 2013 | 47 | 0.420 |
Why?
| | Emergency Service, Hospital | 7 | 2025 | 2069 | 0.410 |
Why?
| | Egg Hypersensitivity | 4 | 2016 | 27 | 0.410 |
Why?
| | Cockroaches | 5 | 2021 | 22 | 0.400 |
Why?
| | Desensitization, Immunologic | 4 | 2016 | 96 | 0.400 |
Why?
| | Models, Theoretical | 1 | 2016 | 578 | 0.400 |
Why?
| | Spirometry | 7 | 2024 | 281 | 0.390 |
Why?
| | Leukocytes, Mononuclear | 8 | 2021 | 558 | 0.380 |
Why?
| | Epigenesis, Genetic | 6 | 2018 | 660 | 0.360 |
Why?
| | Risk Factors | 17 | 2025 | 10388 | 0.360 |
Why?
| | Nicotine | 1 | 2013 | 334 | 0.350 |
Why?
| | Disease Management | 5 | 2025 | 628 | 0.340 |
Why?
| | Hypersensitivity, Immediate | 3 | 2012 | 44 | 0.320 |
Why?
| | Arachis | 5 | 2015 | 112 | 0.320 |
Why?
| | Stress, Psychological | 1 | 2018 | 1100 | 0.320 |
Why?
| | Infant | 19 | 2024 | 9465 | 0.310 |
Why?
| | Picornaviridae Infections | 3 | 2024 | 47 | 0.300 |
Why?
| | Receptors, Pattern Recognition | 1 | 2008 | 11 | 0.300 |
Why?
| | Maxillary Sinus | 2 | 2009 | 11 | 0.300 |
Why?
| | Primary Health Care | 3 | 2021 | 1738 | 0.300 |
Why?
| | Bacterial Infections | 2 | 2008 | 250 | 0.290 |
Why?
| | Prospective Studies | 10 | 2025 | 7604 | 0.290 |
Why?
| | Environmental Monitoring | 3 | 2025 | 370 | 0.290 |
Why?
| | Urban Health | 4 | 2013 | 92 | 0.280 |
Why?
| | Environmental Microbiology | 2 | 2007 | 53 | 0.270 |
Why?
| | Precision Medicine | 2 | 2021 | 429 | 0.270 |
Why?
| | DNA Methylation | 5 | 2018 | 643 | 0.260 |
Why?
| | Fluticasone | 6 | 2018 | 90 | 0.250 |
Why?
| | Immune System | 1 | 2007 | 177 | 0.250 |
Why?
| | Epithelial Cells | 3 | 2024 | 1096 | 0.250 |
Why?
| | Sinusitis | 1 | 2009 | 221 | 0.250 |
Why?
| | Practice Guidelines as Topic | 7 | 2018 | 1587 | 0.250 |
Why?
| | Antibodies, Anti-Idiotypic | 3 | 2013 | 59 | 0.250 |
Why?
| | Biomarkers | 6 | 2022 | 4149 | 0.240 |
Why?
| | Dermatitis, Atopic | 5 | 2014 | 329 | 0.240 |
Why?
| | United States | 14 | 2025 | 14841 | 0.240 |
Why?
| | Baltimore | 2 | 2016 | 60 | 0.240 |
Why?
| | Transcriptome | 4 | 2022 | 971 | 0.230 |
Why?
| | Adrenergic beta-Agonists | 2 | 2009 | 134 | 0.230 |
Why?
| | Antibodies, Monoclonal | 3 | 2020 | 1430 | 0.230 |
Why?
| | Pulmonary Surfactant-Associated Protein A | 1 | 2024 | 35 | 0.230 |
Why?
| | Maxillary Sinusitis | 1 | 2004 | 7 | 0.220 |
Why?
| | Recurrence | 3 | 2024 | 1060 | 0.220 |
Why?
| | Respiratory Tract Infections | 2 | 2019 | 390 | 0.210 |
Why?
| | Medicaid | 2 | 2024 | 435 | 0.210 |
Why?
| | Skin Tests | 7 | 2014 | 101 | 0.200 |
Why?
| | Host-Pathogen Interactions | 2 | 2017 | 364 | 0.200 |
Why?
| | Treatment Outcome | 14 | 2024 | 10811 | 0.200 |
Why?
| | Cities | 2 | 2018 | 133 | 0.200 |
Why?
| | Biological Factors | 1 | 2023 | 39 | 0.200 |
Why?
| | Maternal Exposure | 2 | 2018 | 190 | 0.200 |
Why?
| | Immunity, Innate | 1 | 2008 | 828 | 0.200 |
Why?
| | Pulmonary Eosinophilia | 1 | 2022 | 27 | 0.190 |
Why?
| | Eosinophils | 3 | 2019 | 332 | 0.190 |
Why?
| | Rhinitis, Allergic, Perennial | 2 | 2016 | 23 | 0.190 |
Why?
| | Pulmonary Surfactants | 1 | 2023 | 106 | 0.190 |
Why?
| | Self Care | 1 | 2005 | 380 | 0.190 |
Why?
| | Quality of Life | 2 | 2021 | 2892 | 0.190 |
Why?
| | DNA, Bacterial | 1 | 2003 | 337 | 0.190 |
Why?
| | Pediatrics | 1 | 2010 | 1101 | 0.190 |
Why?
| | Forced Expiratory Volume | 5 | 2017 | 531 | 0.190 |
Why?
| | Antibodies, Monoclonal, Humanized | 5 | 2022 | 804 | 0.190 |
Why?
| | Administration, Inhalation | 6 | 2016 | 688 | 0.180 |
Why?
| | Milk Hypersensitivity | 2 | 2012 | 19 | 0.180 |
Why?
| | CpG Islands | 2 | 2018 | 157 | 0.180 |
Why?
| | Early Growth Response Protein 1 | 1 | 2021 | 27 | 0.180 |
Why?
| | Respiratory Syncytial Virus Infections | 2 | 2018 | 128 | 0.180 |
Why?
| | Double-Blind Method | 10 | 2016 | 1993 | 0.180 |
Why?
| | Gene Expression Profiling | 4 | 2017 | 1774 | 0.170 |
Why?
| | Immune Tolerance | 2 | 2014 | 363 | 0.170 |
Why?
| | Tobacco Smoke Pollution | 3 | 2016 | 261 | 0.170 |
Why?
| | Mucin 5AC | 1 | 2021 | 70 | 0.170 |
Why?
| | Housing | 4 | 2021 | 146 | 0.170 |
Why?
| | Surveys and Questionnaires | 4 | 2018 | 5778 | 0.170 |
Why?
| | Quantitative Trait Loci | 3 | 2021 | 380 | 0.170 |
Why?
| | Anti-Allergic Agents | 2 | 2018 | 46 | 0.170 |
Why?
| | Enterovirus Infections | 1 | 2023 | 177 | 0.170 |
Why?
| | Nitric Oxide | 4 | 2015 | 915 | 0.160 |
Why?
| | Intellectual Disability | 1 | 2021 | 165 | 0.160 |
Why?
| | Bronchial Hyperreactivity | 3 | 2012 | 111 | 0.160 |
Why?
| | Cross-Sectional Studies | 7 | 2020 | 5472 | 0.160 |
Why?
| | Gene Expression Regulation | 6 | 2021 | 2607 | 0.160 |
Why?
| | ERG1 Potassium Channel | 1 | 2018 | 6 | 0.150 |
Why?
| | Interleukin-5 Receptor alpha Subunit | 1 | 2018 | 6 | 0.150 |
Why?
| | Androstadienes | 3 | 2009 | 107 | 0.150 |
Why?
| | Decision Making, Computer-Assisted | 1 | 2018 | 18 | 0.150 |
Why?
| | Autoimmune Diseases | 1 | 2003 | 460 | 0.150 |
Why?
| | Adult | 20 | 2022 | 37929 | 0.150 |
Why?
| | Albuterol | 4 | 2025 | 110 | 0.150 |
Why?
| | Randomized Controlled Trials as Topic | 3 | 2021 | 1477 | 0.150 |
Why?
| | Genotype | 2 | 2021 | 1916 | 0.150 |
Why?
| | Chromosomes, Human, Pair 17 | 1 | 2018 | 55 | 0.140 |
Why?
| | Respiratory System | 1 | 2019 | 157 | 0.140 |
Why?
| | Eczema | 2 | 2010 | 69 | 0.140 |
Why?
| | Nutrition Surveys | 4 | 2014 | 266 | 0.140 |
Why?
| | Acute Disease | 1 | 2020 | 1007 | 0.140 |
Why?
| | Age of Onset | 2 | 2016 | 518 | 0.130 |
Why?
| | Interleukin-6 | 2 | 2020 | 778 | 0.130 |
Why?
| | Lipopolysaccharides | 3 | 2008 | 886 | 0.130 |
Why?
| | Seasons | 5 | 2022 | 547 | 0.130 |
Why?
| | RNA Virus Infections | 1 | 2017 | 15 | 0.130 |
Why?
| | Fluticasone-Salmeterol Drug Combination | 1 | 2016 | 12 | 0.130 |
Why?
| | Infant, Newborn | 5 | 2024 | 6079 | 0.130 |
Why?
| | RNA, Ribosomal, 16S | 1 | 2019 | 549 | 0.130 |
Why?
| | Gene Regulatory Networks | 1 | 2019 | 305 | 0.130 |
Why?
| | Age Factors | 4 | 2006 | 3295 | 0.130 |
Why?
| | Basophils | 3 | 2015 | 73 | 0.130 |
Why?
| | Guideline Adherence | 1 | 2021 | 556 | 0.130 |
Why?
| | Epidemiologic Studies | 1 | 2016 | 72 | 0.130 |
Why?
| | RNA Viruses | 1 | 2017 | 43 | 0.130 |
Why?
| | Follow-Up Studies | 6 | 2018 | 5131 | 0.130 |
Why?
| | Plasma Cells | 2 | 2009 | 71 | 0.130 |
Why?
| | Medical History Taking | 1 | 2016 | 117 | 0.130 |
Why?
| | Feasibility Studies | 1 | 2020 | 956 | 0.130 |
Why?
| | Immunization | 2 | 2016 | 411 | 0.130 |
Why?
| | Antiviral Agents | 2 | 2023 | 744 | 0.120 |
Why?
| | Lung | 3 | 2023 | 4060 | 0.120 |
Why?
| | Immune System Diseases | 1 | 2015 | 39 | 0.120 |
Why?
| | Sublingual Immunotherapy | 1 | 2015 | 5 | 0.120 |
Why?
| | Polymorphism, Single Nucleotide | 3 | 2021 | 2189 | 0.120 |
Why?
| | Cluster Analysis | 1 | 2016 | 499 | 0.120 |
Why?
| | Socioeconomic Factors | 3 | 2016 | 1289 | 0.120 |
Why?
| | Genome-Wide Association Study | 3 | 2018 | 1431 | 0.110 |
Why?
| | Longitudinal Studies | 3 | 2019 | 2844 | 0.110 |
Why?
| | Neoplasm Proteins | 1 | 2018 | 434 | 0.110 |
Why?
| | Down Syndrome | 1 | 2021 | 496 | 0.110 |
Why?
| | Rural Health | 2 | 2006 | 80 | 0.110 |
Why?
| | Metabolic Diseases | 1 | 2015 | 108 | 0.110 |
Why?
| | Schools | 1 | 2018 | 461 | 0.110 |
Why?
| | Air Pollution | 1 | 2018 | 316 | 0.110 |
Why?
| | Antigens, Plant | 1 | 2014 | 54 | 0.110 |
Why?
| | Dendritic Cells | 1 | 2017 | 483 | 0.110 |
Why?
| | Young Adult | 10 | 2018 | 13209 | 0.110 |
Why?
| | Infant, Premature | 1 | 2018 | 574 | 0.110 |
Why?
| | Specimen Handling | 1 | 2015 | 183 | 0.110 |
Why?
| | Parents | 2 | 2022 | 1347 | 0.110 |
Why?
| | Physician-Patient Relations | 1 | 2018 | 548 | 0.110 |
Why?
| | Respiratory Hypersensitivity | 1 | 2014 | 69 | 0.100 |
Why?
| | Gene Expression | 1 | 2018 | 1502 | 0.100 |
Why?
| | Animals | 10 | 2021 | 36940 | 0.100 |
Why?
| | Leukotriene E4 | 2 | 2012 | 27 | 0.100 |
Why?
| | Combined Modality Therapy | 1 | 2016 | 1236 | 0.100 |
Why?
| | Enterovirus | 2 | 2024 | 86 | 0.100 |
Why?
| | Research | 1 | 2016 | 451 | 0.100 |
Why?
| | Telemedicine | 1 | 2022 | 862 | 0.100 |
Why?
| | Genetic Predisposition to Disease | 2 | 2021 | 2426 | 0.100 |
Why?
| | Bronchiolitis | 2 | 2024 | 80 | 0.100 |
Why?
| | Neutrophils | 2 | 2009 | 1238 | 0.100 |
Why?
| | Biopsy | 2 | 2009 | 1129 | 0.100 |
Why?
| | Prognosis | 4 | 2017 | 4030 | 0.100 |
Why?
| | Hospitalization | 2 | 2021 | 2199 | 0.090 |
Why?
| | Indians, North American | 1 | 2018 | 643 | 0.090 |
Why?
| | Cohort Studies | 5 | 2025 | 5742 | 0.090 |
Why?
| | Adaptive Clinical Trials as Topic | 2 | 2021 | 22 | 0.090 |
Why?
| | Homeostasis | 1 | 2015 | 621 | 0.090 |
Why?
| | Membrane Proteins | 1 | 2018 | 1164 | 0.090 |
Why?
| | Influenza, Human | 1 | 2017 | 622 | 0.090 |
Why?
| | Predictive Value of Tests | 3 | 2017 | 2031 | 0.090 |
Why?
| | Decision Making | 1 | 2018 | 900 | 0.090 |
Why?
| | Obesity | 2 | 2018 | 2992 | 0.090 |
Why?
| | Vitamin D Deficiency | 1 | 2013 | 186 | 0.090 |
Why?
| | Time Factors | 3 | 2016 | 6828 | 0.090 |
Why?
| | Case-Control Studies | 3 | 2019 | 3556 | 0.090 |
Why?
| | Rhinitis, Allergic, Seasonal | 1 | 2010 | 29 | 0.080 |
Why?
| | Chronic Disease | 2 | 2009 | 1793 | 0.080 |
Why?
| | Comorbidity | 2 | 2015 | 1622 | 0.080 |
Why?
| | Nedocromil | 1 | 2010 | 32 | 0.080 |
Why?
| | Logistic Models | 3 | 2010 | 2074 | 0.080 |
Why?
| | Genomics | 1 | 2015 | 795 | 0.080 |
Why?
| | Physicians | 1 | 2018 | 910 | 0.080 |
Why?
| | Budesonide | 1 | 2010 | 89 | 0.080 |
Why?
| | Vitamin D | 1 | 2013 | 397 | 0.080 |
Why?
| | Models, Statistical | 1 | 2013 | 669 | 0.080 |
Why?
| | Hexosaminidases | 1 | 2009 | 18 | 0.080 |
Why?
| | Food | 1 | 2010 | 164 | 0.080 |
Why?
| | Immunoenzyme Techniques | 1 | 2009 | 219 | 0.080 |
Why?
| | Health Personnel | 1 | 2015 | 710 | 0.070 |
Why?
| | Immunoglobulin G | 4 | 2014 | 893 | 0.070 |
Why?
| | Staining and Labeling | 1 | 2009 | 150 | 0.070 |
Why?
| | Curriculum | 1 | 2015 | 992 | 0.070 |
Why?
| | Peroxidase | 1 | 2009 | 175 | 0.070 |
Why?
| | Natural Killer T-Cells | 1 | 2009 | 67 | 0.070 |
Why?
| | RNA | 1 | 2015 | 921 | 0.070 |
Why?
| | Polysaccharides, Bacterial | 1 | 2008 | 70 | 0.070 |
Why?
| | Exhalation | 3 | 2015 | 39 | 0.070 |
Why?
| | DNA | 1 | 2015 | 1459 | 0.070 |
Why?
| | Glucocorticoids | 2 | 2011 | 594 | 0.070 |
Why?
| | Health Services Accessibility | 1 | 2015 | 986 | 0.070 |
Why?
| | Prednisone | 1 | 2008 | 240 | 0.070 |
Why?
| | Adrenergic beta-2 Receptor Agonists | 2 | 2018 | 37 | 0.070 |
Why?
| | Gene Frequency | 2 | 2021 | 521 | 0.070 |
Why?
| | Infant Care | 1 | 2007 | 45 | 0.070 |
Why?
| | Macrophage Activation | 1 | 2008 | 201 | 0.070 |
Why?
| | Chromatography, High Pressure Liquid | 1 | 2009 | 597 | 0.070 |
Why?
| | Community Health Nursing | 1 | 2007 | 61 | 0.070 |
Why?
| | Pulmonary Disease, Chronic Obstructive | 1 | 2015 | 1040 | 0.070 |
Why?
| | Dexamethasone | 2 | 2025 | 368 | 0.070 |
Why?
| | Retrospective Studies | 4 | 2025 | 15657 | 0.060 |
Why?
| | C-Reactive Protein | 1 | 2009 | 410 | 0.060 |
Why?
| | Sequence Analysis, RNA | 2 | 2021 | 452 | 0.060 |
Why?
| | Manure | 1 | 2006 | 8 | 0.060 |
Why?
| | Tandem Mass Spectrometry | 1 | 2009 | 532 | 0.060 |
Why?
| | Patient Education as Topic | 1 | 2011 | 766 | 0.060 |
Why?
| | Tumor Necrosis Factor-alpha | 2 | 2018 | 1242 | 0.060 |
Why?
| | Clinical Trials, Phase III as Topic | 1 | 2006 | 106 | 0.060 |
Why?
| | Antigens, CD | 1 | 2009 | 521 | 0.060 |
Why?
| | India | 1 | 2006 | 195 | 0.060 |
Why?
| | Risk Assessment | 2 | 2006 | 3457 | 0.060 |
Why?
| | Maximum Tolerated Dose | 1 | 2006 | 199 | 0.060 |
Why?
| | Electronics, Medical | 1 | 2005 | 13 | 0.060 |
Why?
| | Biomedical Research | 1 | 2012 | 692 | 0.060 |
Why?
| | Bronchial Provocation Tests | 1 | 2005 | 51 | 0.060 |
Why?
| | Interferon-alpha | 2 | 2017 | 198 | 0.060 |
Why?
| | Environment | 1 | 2007 | 358 | 0.060 |
Why?
| | Patient Compliance | 1 | 2009 | 581 | 0.060 |
Why?
| | Virus Attachment | 1 | 2024 | 16 | 0.060 |
Why?
| | Salmeterol Xinafoate | 2 | 2018 | 41 | 0.060 |
Why?
| | Research Design | 2 | 2021 | 1139 | 0.060 |
Why?
| | Exocrine Glands | 1 | 2004 | 5 | 0.050 |
Why?
| | Basement Membrane | 1 | 2004 | 35 | 0.050 |
Why?
| | Histamine H1 Antagonists | 1 | 2004 | 30 | 0.050 |
Why?
| | Macrophages | 2 | 2009 | 1547 | 0.050 |
Why?
| | ROC Curve | 1 | 2025 | 554 | 0.050 |
Why?
| | Leukotrienes | 1 | 2004 | 37 | 0.050 |
Why?
| | Drug Administration Schedule | 1 | 2006 | 786 | 0.050 |
Why?
| | Interleukin-12 Subunit p40 | 1 | 2003 | 9 | 0.050 |
Why?
| | Administration, Sublingual | 2 | 2013 | 12 | 0.050 |
Why?
| | Interleukin-13 | 2 | 2015 | 149 | 0.050 |
Why?
| | Cells, Cultured | 3 | 2018 | 4193 | 0.050 |
Why?
| | B-Lymphocytes | 1 | 2009 | 847 | 0.050 |
Why?
| | Cell Count | 1 | 2004 | 324 | 0.050 |
Why?
| | Interleukin-12 | 1 | 2003 | 121 | 0.050 |
Why?
| | Disease Outbreaks | 1 | 2006 | 395 | 0.050 |
Why?
| | Administration, Topical | 1 | 2003 | 151 | 0.050 |
Why?
| | Agriculture | 1 | 2003 | 103 | 0.050 |
Why?
| | Cysteine | 1 | 2004 | 204 | 0.050 |
Why?
| | Protein Subunits | 1 | 2003 | 239 | 0.050 |
Why?
| | Particulate Matter | 1 | 2025 | 315 | 0.050 |
Why?
| | Breast Feeding | 1 | 2006 | 440 | 0.050 |
Why?
| | Interleukin-4 | 2 | 2015 | 216 | 0.050 |
Why?
| | Epithelium | 1 | 2023 | 313 | 0.050 |
Why?
| | Clinical Trials, Phase II as Topic | 1 | 2021 | 76 | 0.050 |
Why?
| | Middle Aged | 6 | 2016 | 33479 | 0.050 |
Why?
| | Lymphocytes | 1 | 2004 | 397 | 0.050 |
Why?
| | In Vitro Techniques | 1 | 2003 | 1092 | 0.050 |
Why?
| | Dose-Response Relationship, Drug | 1 | 2006 | 2057 | 0.050 |
Why?
| | Interleukin-10 | 1 | 2003 | 302 | 0.050 |
Why?
| | Nasal Provocation Tests | 1 | 2021 | 3 | 0.040 |
Why?
| | Disease Susceptibility | 1 | 2003 | 347 | 0.040 |
Why?
| | Th1 Cells | 1 | 2002 | 143 | 0.040 |
Why?
| | Practice Patterns, Physicians' | 1 | 2010 | 1313 | 0.040 |
Why?
| | Inflammation | 3 | 2020 | 2837 | 0.040 |
Why?
| | Hydrocortisone | 1 | 2003 | 322 | 0.040 |
Why?
| | Cytokines | 1 | 2008 | 2085 | 0.040 |
Why?
| | T-Lymphocytes | 1 | 2009 | 1996 | 0.040 |
Why?
| | Fungi | 1 | 2021 | 144 | 0.040 |
Why?
| | Breath Tests | 2 | 2012 | 87 | 0.040 |
Why?
| | Advisory Committees | 1 | 2021 | 219 | 0.040 |
Why?
| | Clinical Protocols | 1 | 2021 | 271 | 0.040 |
Why?
| | Social Determinants of Health | 1 | 2024 | 267 | 0.040 |
Why?
| | A549 Cells | 1 | 2019 | 66 | 0.040 |
Why?
| | Lymphocyte Activation | 1 | 2003 | 1142 | 0.040 |
Why?
| | Common Cold | 1 | 2019 | 13 | 0.040 |
Why?
| | Anti-Inflammatory Agents | 1 | 2003 | 496 | 0.040 |
Why?
| | Diagnosis, Differential | 1 | 2003 | 1483 | 0.040 |
Why?
| | Immunotherapy | 1 | 2004 | 641 | 0.040 |
Why?
| | Linear Models | 2 | 2013 | 849 | 0.040 |
Why?
| | Vitamin D3 24-Hydroxylase | 1 | 2018 | 15 | 0.040 |
Why?
| | Chicago | 1 | 2018 | 61 | 0.040 |
Why?
| | Tacrolimus Binding Proteins | 1 | 2018 | 27 | 0.040 |
Why?
| | Lipids | 1 | 2023 | 672 | 0.040 |
Why?
| | Analysis of Variance | 2 | 2015 | 1316 | 0.040 |
Why?
| | Monitoring, Physiologic | 1 | 2020 | 275 | 0.040 |
Why?
| | Environmental Pollution | 1 | 2018 | 20 | 0.040 |
Why?
| | Maternal Health | 1 | 2018 | 49 | 0.030 |
Why?
| | Family | 1 | 2022 | 671 | 0.030 |
Why?
| | Cell Death | 1 | 2019 | 374 | 0.030 |
Why?
| | Interleukin-8 | 1 | 2018 | 268 | 0.030 |
Why?
| | Morbidity | 1 | 2018 | 324 | 0.030 |
Why?
| | Caregivers | 1 | 2005 | 877 | 0.030 |
Why?
| | Receptors, Glucocorticoid | 1 | 2018 | 155 | 0.030 |
Why?
| | Adrenergic beta-1 Receptor Agonists | 1 | 2016 | 5 | 0.030 |
Why?
| | Metered Dose Inhalers | 1 | 2016 | 16 | 0.030 |
Why?
| | Vital Capacity | 1 | 2017 | 311 | 0.030 |
Why?
| | Folic Acid | 1 | 2018 | 186 | 0.030 |
Why?
| | Gene Expression Regulation, Viral | 1 | 2017 | 95 | 0.030 |
Why?
| | Evidence-Based Practice | 1 | 2018 | 229 | 0.030 |
Why?
| | Child Health | 1 | 2018 | 154 | 0.030 |
Why?
| | Signal Transduction | 2 | 2020 | 5079 | 0.030 |
Why?
| | Bronchoalveolar Lavage Fluid | 2 | 2008 | 652 | 0.030 |
Why?
| | Delayed-Action Preparations | 1 | 2016 | 181 | 0.030 |
Why?
| | Models, Biological | 1 | 2003 | 1783 | 0.030 |
Why?
| | Core Binding Factor Alpha 3 Subunit | 1 | 2015 | 6 | 0.030 |
Why?
| | Bacteria | 1 | 2022 | 858 | 0.030 |
Why?
| | Interleukin-1 Receptor-Like 1 Protein | 1 | 2015 | 26 | 0.030 |
Why?
| | Patient Participation | 1 | 2018 | 420 | 0.030 |
Why?
| | Respiratory Mucosa | 1 | 2017 | 321 | 0.030 |
Why?
| | Plant Proteins | 1 | 2014 | 113 | 0.030 |
Why?
| | Cross Reactions | 1 | 2014 | 133 | 0.030 |
Why?
| | Receptors, Immunologic | 1 | 2015 | 216 | 0.030 |
Why?
| | Community Health Services | 1 | 2015 | 227 | 0.030 |
Why?
| | Aged, 80 and over | 2 | 2016 | 7635 | 0.030 |
Why?
| | High-Throughput Nucleotide Sequencing | 1 | 2017 | 539 | 0.030 |
Why?
| | Proportional Hazards Models | 1 | 2016 | 1266 | 0.030 |
Why?
| | Th2 Cells | 1 | 2014 | 176 | 0.020 |
Why?
| | Receptors, Cell Surface | 1 | 2015 | 385 | 0.020 |
Why?
| | Models, Genetic | 1 | 2015 | 600 | 0.020 |
Why?
| | Eggs | 1 | 2012 | 25 | 0.020 |
Why?
| | Alleles | 1 | 2015 | 891 | 0.020 |
Why?
| | Bronchi | 1 | 2014 | 260 | 0.020 |
Why?
| | Milk | 1 | 2012 | 124 | 0.020 |
Why?
| | Mexican Americans | 1 | 2013 | 120 | 0.020 |
Why?
| | Patient Acceptance of Health Care | 1 | 2018 | 806 | 0.020 |
Why?
| | Odds Ratio | 1 | 2014 | 1070 | 0.020 |
Why?
| | Pregnancy | 2 | 2018 | 6763 | 0.020 |
Why?
| | Tomography, X-Ray Computed | 1 | 2021 | 2691 | 0.020 |
Why?
| | Prenatal Exposure Delayed Effects | 1 | 2018 | 605 | 0.020 |
Why?
| | Reproducibility of Results | 2 | 2009 | 3284 | 0.020 |
Why?
| | Poverty Areas | 1 | 2011 | 39 | 0.020 |
Why?
| | Drug Utilization | 1 | 2012 | 169 | 0.020 |
Why?
| | Evidence-Based Medicine | 1 | 2015 | 740 | 0.020 |
Why?
| | CD4-Positive T-Lymphocytes | 1 | 2017 | 1091 | 0.020 |
Why?
| | Critical Care | 1 | 2015 | 601 | 0.020 |
Why?
| | Sputum | 1 | 2012 | 311 | 0.020 |
Why?
| | Administration, Oral | 1 | 2012 | 816 | 0.020 |
Why?
| | Quality Improvement | 1 | 2018 | 1178 | 0.020 |
Why?
| | Aged | 3 | 2016 | 23961 | 0.020 |
Why?
| | Histamine Release | 1 | 2009 | 21 | 0.020 |
Why?
| | Cyclopropanes | 1 | 2009 | 90 | 0.020 |
Why?
| | Multivariate Analysis | 1 | 2013 | 1509 | 0.020 |
Why?
| | Cell Degranulation | 1 | 2009 | 41 | 0.020 |
Why?
| | Receptors, IgE | 1 | 2009 | 45 | 0.020 |
Why?
| | Risk | 1 | 2012 | 912 | 0.020 |
Why?
| | Acetates | 1 | 2009 | 99 | 0.020 |
Why?
| | Sulfides | 1 | 2009 | 99 | 0.020 |
Why?
| | Pilot Projects | 1 | 2013 | 1710 | 0.020 |
Why?
| | Quinolines | 1 | 2009 | 178 | 0.020 |
Why?
| | Drug Therapy, Combination | 1 | 2011 | 1066 | 0.020 |
Why?
| | Drug Resistance | 1 | 2008 | 169 | 0.020 |
Why?
| | Sickness Impact Profile | 1 | 2007 | 56 | 0.020 |
Why?
| | Health Surveys | 1 | 2009 | 514 | 0.020 |
Why?
| | Respiratory Physiological Phenomena | 1 | 2006 | 31 | 0.020 |
Why?
| | Oligonucleotide Array Sequence Analysis | 1 | 2008 | 767 | 0.020 |
Why?
| | Vulnerable Populations | 1 | 2007 | 163 | 0.020 |
Why?
| | Growth | 1 | 2006 | 60 | 0.020 |
Why?
| | Monocytes | 1 | 2008 | 563 | 0.010 |
Why?
| | Cotinine | 1 | 2005 | 77 | 0.010 |
Why?
| | Cats | 1 | 2005 | 210 | 0.010 |
Why?
| | Sensitivity and Specificity | 1 | 2009 | 1946 | 0.010 |
Why?
| | Disease-Free Survival | 1 | 2006 | 686 | 0.010 |
Why?
| | Algorithms | 1 | 2012 | 1704 | 0.010 |
Why?
| | Regression Analysis | 1 | 2006 | 1024 | 0.010 |
Why?
| | Dogs | 1 | 2005 | 413 | 0.010 |
Why?
| | Cell Line | 1 | 2009 | 2847 | 0.010 |
Why?
| | Program Evaluation | 1 | 2007 | 898 | 0.010 |
Why?
| | Home Care Services | 1 | 2005 | 257 | 0.010 |
Why?
| | Body Mass Index | 1 | 2009 | 2389 | 0.010 |
Why?
| | Rats | 1 | 2009 | 5647 | 0.010 |
Why?
| | Health Knowledge, Attitudes, Practice | 1 | 2005 | 1329 | 0.010 |
Why?
| | Colorado | 1 | 2005 | 4565 | 0.010 |
Why?
|
|
Liu's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors  People in Profiles who have published with this person. _
Similar People  People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors  People whose addresses are nearby this person. _
|